RA patients are receiving recommended cancer screenings

Share this article:
RA Patients Are Receiving Recommended Cancer Screenings
RA Patients Are Receiving Recommended Cancer Screenings

(HealthDay News) -- Patients with rheumatoid arthritis (RA) receive cancer screening tests at higher rates than that of the general population, according to a study published online July 10 in Arthritis & Rheumatism.

Using data from a large U.S. commercial insurance plan, Seoyoung C. Kim, M.D., from Brigham and Women's Hospital in Boston, and colleagues compared cancer screening rates for patients with and without RA. RA was identified as two or more diagnoses of RA and at least one prescription for a disease-modifying anti-rheumatic drug.

The researchers found that, over a mean of 2.3 years of follow-up, both RA and non-RA patients were screened, on average, once every three years for cervical cancer and once every two years for breast cancer. Adjusting for age, women with RA were more likely than non-RA patients to receive one or more of each of the following tests: Papanicolaou smear (hazard ratio [HR], 1.21; 95 percent confidence interval [CI], 1.17 to 1.24), mammogram (HR, 1.49; 95 percent CI, 1.45 to 1.53), and colonoscopy (HR, 1.69; 95 percent CI, 1.61 to 1.77). Similarly, men with RA were more likely than non-RA patients to receive a colonoscopy (HR, 1.52; 95 percent CI, 1.40 to 1.64). These results persisted when adjusting for age, number of physician visits, percent of visits made to primary care physicians, and comorbidity index.

"Individuals with RA did not appear to be at risk for receiving fewer cancer screening tests than non-RA patients," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Poor parent-provider communication seen in advanced pediatric cancer

Poor parent-provider communication seen in advanced pediatric cancer

For pediatric patients with advanced cancer, parent-provider concordance is poor regarding prognosis and goals of care, according to a study.

Testicular cancer on the rise for young U.S. Hispanics

Testicular cancer on the rise for young U.S. ...

An increase in incidence of testicular germ cell tumors in Hispanic adolescents and young adults in the United States has been observed.

Rates of observation as prostate cancer management vary

Rates of observation as prostate cancer management vary

Rates of observation as management for low-risk prostate cancer vary widely, and primary ADT is not tied to better survival for men with localized prostate cancer.